Further, a handful of trials in the mid-later 1990s compared ACE (angiotensin-converting enzyme) inhibitors, calcium channel blockers, and the alpha-blocker doxazosin with thiazide diuretics, thiazide/beta-blocker combination or chlorthalidone (Table) and found no differences in the primary end points, which were cardiovascular mortality, a composite of stroke, myocardial infarction and cardiovascular mortality, or incident myocardial infarction and fatal coronary disease. The gene discussed is ACE; the disease is coronary artery disorder.